PIK3CA Y1021C

CI-VAR-00004740Explore in graph →NP_006209.2:p.Tyr1021CysNM_006218.3:c.3062A>GClinVar 376246 CIViC 935 rs121913288

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
PIK3CA Y1021C	PI103	Predictive	D	Supports Sensitivity Response	—	submitted	EID2364 In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC) PMID 19513541 · Zou et al., 2009 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
376246	Pathogenic	criteria provided, single submitter	1	Abnormal cardiovascular system morphology; Cowden syndrome; Neoplasm; Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype	germline/somatic	4	Nov 04, 2021	clinvar